钯-103与碘-125低剂量率前列腺近距离放疗单疗法后的结局:一项国际多机构研究
一项国际多机构回顾性分析比较了钯-103(n=1,597)与碘-125(n=7,504)低剂量率前列腺近距离放疗单疗法的肿瘤学结局。钯-103组7年无生化失败率(96.2% vs 87.6%,P<0.001)和无临床失败率(96.5% vs 94.3%,P<0.001)均更高,多因素校正后差异仍显著(无生化失败HR=0.31,无临床失败HR=0.49,均P<0.001),生化治愈率亦更高(多因素OR=6.0,P<0.001)。
要点
- 钯-103组7年无生化失败率96.2% vs 碘-125组87.6%(P<0.001),无临床失败率96.5% vs 94.3%(P<0.001)。
- 多因素校正后钯-103仍与更高无生化失败(HR=0.31)和无临床失败(HR=0.49)相关,均P<0.001。
- 钯-103组生化治愈率更高,多因素分析OR=6.0(P<0.001)。
核心结论
- 钯-103单疗法与更高的无生化失败率、无临床失败率和生化治愈率相关,提示钯-103低剂量率近距离放疗可能较碘-125改善肿瘤学结局。
研究设计与样本
- 回顾性分析8家机构数据库,纳入接受 definitive 低剂量率近距离放疗单疗法的前列腺癌男性,钯-103组n=1,597,碘-125组n=7,504。
- 采用Kaplan-Meier单因素和Cox多因素分析比较按同位素分层的无临床失败率和无生化失败率。
- 对随访至少3.5年的男性计算生化治愈率(随访3.5至4.5年间前列腺特异性抗原水平≤0.2 ng/mL),并采用单因素和多因素逻辑回归比较。
主要发现
- 与碘-125组相比,钯-103组7年无生化失败率更高(96.2% vs 87.6%,P<0.001),7年无临床失败率更高(96.5% vs 94.3%,P<0.001)。
- 多因素校正基线因素后差异仍显著:无生化失败HR=0.31,无临床失败HR=0.49,均P<0.001。
- 钯-103与更高生化治愈率相关:单因素分析OR=5.9(P<0.001),多因素分析OR=6.0(P<0.001)。
- 在同时使用两种同位素的4家机构数据(n=2,971)的敏感性分析中,结果仍保持显著性。
关键数值与推荐
- 无生化失败率:钯-103组96.2% vs 碘-125组87.6%(7年,P<0.001)。
- 无临床失败率:钯-103组96.5% vs 碘-125组94.3%(7年,P<0.001)。
- 多因素校正后无生化失败HR=0.31(P<0.001),无临床失败HR=0.49(P<0.001)。
- 生化治愈率(PSA≤0.2 ng/mL,随访3.5至4.5年):多因素分析OR=6.0(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Pd-103 and I-125 are commonly used in low dose rate (LDR) brachytherapy for prostate cancer. Comparisons of outcomes by isotope type are limited, but Pd-103 has distinct radiobiologic advantages over I-125 despite its lesser availability outside the United States. We evaluated oncologic outcomes after Pd-103 vs I-125 LDR monotherapy for prostate cancer. MATERIALS AND METHODS: We retrospectively analyzed databases at 8 institutions for men who received definitive LDR monotherapy with Pd-103 (n = 1,597) or I-125 (n = 7,504) for prostate cancer. Freedom from clinical failure (FFCF) and freedom from biochemical failure (FFBF) stratified by isotope were analyzed by Kaplan-Meier univariate and Cox multivariate analyses. Biochemical cure rates (prostate-specific antigen level ≤ 0.2 ng/mL between 3.5 and 4.5 years of follow-up) by isotype were calculated for men with at least 3.5 years of follow-up and compared by univariate and multivariate logistic regression. RESULTS: Compared with I-125, Pd-103 led to higher 7-year rates of FFBF (96.2% vs 87.6%, P < 0.001) and FFCF (96.5% vs 94.3%, P < 0.001). This difference held after multivariate adjustment for baseline factors (FFBF hazard ratio [HR] = 0.31, FFCF HR = 0.49, both P < 0.001). Pd-103 was also associated with higher cure rates on univariate (odds ratio [OR] = 5.9, P < 0.001) and multivariate (OR = 6.0, P < 0.001) analyses. Results retained significance in sensitivity analyses of data from the 4 institutions that used both isotopes (n = 2,971). CONCLUSIONS: Pd-103 monotherapy was associated with higher FFBF, FFCF, and biochemical cure rates, and suggests that Pd-103 LDR may lead to improved oncologic outcomes compared with I-125.
引用
- Tang C, Sanders J, Thames H, et al. Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: An international, multi-institutional study. Radiother Oncol. 2023. PMID: 36889593. doi:10.1016/j.radonc.2023.109599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。